Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback